# EDGAR Filing Document

**Accession Number:** 0001809519
**File Stem:** 0001809519-25-000117
**Filing Date:** 2025-8
**Character Count:** 133406
**Document Hash:** ca35c8741318829a55a7bad4269c0f95
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001809519-25-000117.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001809519-25-000117

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 58

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GoodRx Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001809519
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 475104396
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39549
- **FILM NUMBER:** 251189953

**BUSINESS ADDRESS:**
- **STREET 1:** 2701 OLYMPIC BOULEVARD
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404
- **BUSINESS PHONE:** (855) 268-2822

**MAIL ADDRESS:**
- **STREET 1:** 2701 OLYMPIC BOULEVARD
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404

?xml version='1.0' encoding='ASCII'? gdrx-20250630

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

________________________________

**FORM 10-Q**

________________________________

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2025**

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ______ to ______.**

**Commission File Number: 001-39549**

________________________________

**GoodRx Holdings, Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

________________________________

---

| | |
|:---|:---|
| **Delaware** | **47-5104396** |
| **(State or other jurisdiction of**<br>**incorporation or organization)**<br>| **(I.R.S. Employer**<br>**Identification No.)**<br>|
| **2701 Olympic Boulevard**<br>**Santa Monica, CA**<br>| **90404** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(855) 268-2822**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name, former address and former fiscal year, if changed since last report)**

________________________________

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)**<br>| **Name of each exchange on which registered** |
| Class A common stock, $0.0001 par value per share | GDRX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and

(2) has been subject to such filing requirements for the past 90 days. Yes⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted

pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the

registrant was required to submit such files). Yes⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller

reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting

company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | ⌧ |
| Non-accelerated filer | □ | Smaller reporting company | □ |
| Emerging growth company | □ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

As of July 29, 2025, the registrant had98,580,674 shares of Class A common stock, $0.0001 par value per share, and

248,869,320 shares of Class B common stock, $0.0001 par value per share, outstanding.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements

to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of

1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All

statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking

statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects,"

"plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "forecasts," "predicts,"

"potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in

this Quarterly Report on Form 10-Q include, but are not limited to statements regarding our future results of operations and

financial position, industry and business trends, the anticipated impact of ongoing changes in the U.S. retail pharmacy

landscape and macroeconomic environment, the impact of store closures and the announced bankruptcy of one of our retail

partners on our business, our value proposition, our collaborations and partnerships with third parties, the impact of the

recent volume reduction in one of our integrated savings programs, the anticipated expansion of our condition-specific

subscription program, stock compensation, our stock repurchase program, realizability of deferred tax assets, impacts from

recent tax legislation, our business strategy, our plans, market opportunity and growth and our objectives for future

operations.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these

forward-looking statements largely on our current expectations and projections about future events and financial trends that

we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known

and unknown risks, uncertainties and other important factors that may cause our actual results, performance or

achievements to be materially different from any future results, performance or achievements expressed or implied by the

forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of

growth; our recent growth rates may not be sustainable or indicative of future growth; our ability to achieve broad market

education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers

in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand our

offerings; changes in medication pricing and the significant impact of pricing structures negotiated by industry participants;

our general inability to control the categories and types of prescriptions for which we can offer savings or discounted prices;

our reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma

manufacturers; the competitive nature of industry; risks related to pandemics, epidemics or outbreak of infectious disease;

the accuracy of our estimate of our addressable market and other operational metrics; our ability to respond to changes in

the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive

perception of our platform or maintain and enhance our brand; risks related to any failure to maintain effective internal

control over ﬁnancial reporting; risks related to use of social media, emails, text messages and other messaging channels as

part of our marketing strategy; our dependence on our information technology systems and those of our third-party vendors,

and risks related to any failure or significant disruptions thereof; risks related to government regulation of the internet, e-

commerce, consumer data and privacy, information technology and cybersecurity; risks related to the use of AI and machine

learning in our business; risks related to a decrease in consumer willingness to receive correspondence or any technical,

legal or any other restrictions to send such correspondence; risks related to any failure to comply with applicable data

protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other requirements;

our ability to utilize our net operating loss carryforwards and certain other tax attributes; the risk that we may be unable to

realize expected benefits from our restructuring and cost reduction efforts; our ability to attract, develop, motivate and retain

well-qualified employees; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or

delays in service on our apps or websites or any undetected errors or design faults; our reliance on third-party platforms to

distribute our platform and offerings, including software as-a-service technologies; systems failures or other disruptions in

the operations of these parties on which we depend; risks related to climate change; the increasing focus on environmental

sustainability and social initiatives; risks related to our intellectual property; risks related to operating in the healthcare

industry; risks related to our organizational structure; litigation related risks; our ability to accurately forecast revenue and

appropriately plan our expenses in the future; risks related to general economic factors, natural disasters or other

unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate which could materially

and adversely affect our results of operations; risks related to the healthcare reform legislation and other proposed or future

changes impacting the healthcare industry and healthcare spending which may adversely affect our business, financial

condition and results of operations; as well as the other important factors discussed in the sections entitled "Risk Factors" of

our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 ("2024 10-K") and this Quarterly Report on

Form 10-Qand in our other filings with the Securities and Exchange Commission ("SEC"). The forward-looking statements

in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on

Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be

limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into,

or review of, all potentially available relevant information. These statements are inherently uncertain and investors are

cautioned not to unduly rely upon these statements.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on

Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future

results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date

of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any

forward-looking statements contained in this Quarterly Report on Form 10-Q, whether as a result of any new information,

future events or otherwise.

We periodically post information that may be important to investors on our investor relations website at https://

investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for

complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are

encouraged to consult our website regularly for important information, in addition to following GoodRx's press releases,

filings with the SEC and public conference calls and webcasts. The information contained on, or that may be accessed

through, our website is not incorporated by reference into, and is not a part of, this Quarterly Report on Form 10-Q.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**Table of Contents**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| **[PART I.](#ia7bcc97e7330412a99b7141e522e061e_13)** | **[FINANCIAL INFORMATION](#ia7bcc97e7330412a99b7141e522e061e_13)** |  |
| [Item 1.](#ia7bcc97e7330412a99b7141e522e061e_16) | <u>[Financial Statements](#ia7bcc97e7330412a99b7141e522e061e_16)</u> | [1](#ia7bcc97e7330412a99b7141e522e061e_16) |
|  | <u>[Condensed Consolidated Balance Sheets](#ia7bcc97e7330412a99b7141e522e061e_19)</u> | [1](#ia7bcc97e7330412a99b7141e522e061e_19) |
|  | <u>[Condensed Consolidated Statements of Operations](#ia7bcc97e7330412a99b7141e522e061e_22)</u> | [2](#ia7bcc97e7330412a99b7141e522e061e_22) |
|  | <u>[Condensed Consolidated Statements of Stockholders' Equity](#ia7bcc97e7330412a99b7141e522e061e_25)</u> | [3](#ia7bcc97e7330412a99b7141e522e061e_25) |
|  | <u>[Condensed Consolidated Statements of Cash Flows](#ia7bcc97e7330412a99b7141e522e061e_31)</u> | [5](#ia7bcc97e7330412a99b7141e522e061e_31) |
|  | <u>[Notes to Condensed Consolidated Financial Statements](#ia7bcc97e7330412a99b7141e522e061e_34)</u> | [7](#ia7bcc97e7330412a99b7141e522e061e_34) |
| [Item 2.](#ia7bcc97e7330412a99b7141e522e061e_73) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#ia7bcc97e7330412a99b7141e522e061e_73)</u> | [16](#ia7bcc97e7330412a99b7141e522e061e_73) |
| [Item 3.](#ia7bcc97e7330412a99b7141e522e061e_109) | <u>[Quantitative and Qualitative Disclosures About Market Risk](#ia7bcc97e7330412a99b7141e522e061e_109)</u> | [24](#ia7bcc97e7330412a99b7141e522e061e_109) |
| [Item 4.](#ia7bcc97e7330412a99b7141e522e061e_112) | <u>[Controls and Procedures](#ia7bcc97e7330412a99b7141e522e061e_112)</u> | [24](#ia7bcc97e7330412a99b7141e522e061e_112) |
| **[PART II.](#ia7bcc97e7330412a99b7141e522e061e_115)** | **[OTHER INFORMATION](#ia7bcc97e7330412a99b7141e522e061e_115)** |  |
| [Item 1.](#ia7bcc97e7330412a99b7141e522e061e_118) | <u>[Legal Proceedings](#ia7bcc97e7330412a99b7141e522e061e_118)</u> | [26](#ia7bcc97e7330412a99b7141e522e061e_118) |
| [Item 1A.](#ia7bcc97e7330412a99b7141e522e061e_121) | <u>[Risk Factors](#ia7bcc97e7330412a99b7141e522e061e_121)</u> | [26](#ia7bcc97e7330412a99b7141e522e061e_121) |
| [Item 2.](#ia7bcc97e7330412a99b7141e522e061e_124) | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#ia7bcc97e7330412a99b7141e522e061e_124)</u> | [26](#ia7bcc97e7330412a99b7141e522e061e_124) |
| [Item 3.](#ia7bcc97e7330412a99b7141e522e061e_127) | <u>[Defaults Upon Senior Securities](#ia7bcc97e7330412a99b7141e522e061e_127)</u> | [27](#ia7bcc97e7330412a99b7141e522e061e_127) |
| [Item 4.](#ia7bcc97e7330412a99b7141e522e061e_130) | <u>[Mine Safety Disclosures](#ia7bcc97e7330412a99b7141e522e061e_130)</u> | [27](#ia7bcc97e7330412a99b7141e522e061e_130) |
| [Item 5.](#ia7bcc97e7330412a99b7141e522e061e_133) | <u>[Other Information](#ia7bcc97e7330412a99b7141e522e061e_133)</u> | [27](#ia7bcc97e7330412a99b7141e522e061e_133) |
| [Item 6.](#ia7bcc97e7330412a99b7141e522e061e_139) | <u>[Exhibits](#ia7bcc97e7330412a99b7141e522e061e_139)</u> | [28](#ia7bcc97e7330412a99b7141e522e061e_139) |
|  | <u>[Signatures](#ia7bcc97e7330412a99b7141e522e061e_142)</u> | [29](#ia7bcc97e7330412a99b7141e522e061e_142) |

---

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**GoodRx Holdings, Inc.**

**Condensed Consolidated Balance Sheets**

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| *(in thousands, except par values)* | **June 30, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| Current assets |  |  |
| Cash and cash equivalents | $281318 | $448346 |
| Accounts receivable, net | 189027 | 145934 |
| Prepaid expenses and other current assets | 80269 | 64975 |
| Total current assets | 550614 | 659255 |
| Property and equipment, net | 10732 | 12664 |
| Goodwill | 421719 | 410769 |
| Intangible assets, net | 65566 | 52102 |
| Capitalized software, net | 138287 | 124781 |
| Operating lease right-of-use assets, net | 30692 | 27794 |
| Deferred tax assets, net | 77182 | 77182 |
| Other assets | 23914 | 23520 |
| Total assets | $1318706 | $1388067 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities |  |  |
| Accounts payable | $25411 | $14137 |
| Accrued expenses and other current liabilities | 95677 | 99130 |
| Current portion of debt | 5000 | 5000 |
| Operating lease liabilities, current | 4821 | 5636 |
| Total current liabilities | 130909 | 123903 |
| Debt, net | 484972 | 486711 |
| Operating lease liabilities, net of current portion | 52745 | 46040 |
| Other liabilities | 7049 | 6755 |
| Total liabilities | 675675 | 663409 |
| Commitments and contingencies (Note 8) |  |  |
| Stockholders' equity |  |  |
| Preferred stock, $0.0001 par value; 50,000 shares authorized and nil shares <br>issued and outstanding at June 30, 2025 and December 31, 2024<br>|  |  |
| Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, <br>99,902 and 105,946 shares issued and outstanding at June 30, 2025 and <br>December 31, 2024, respectively; and Class B: 1,000,000 shares authorized, <br>252,869 and 276,869 shares issued and outstanding at June 30, 2025 and <br>December 31, 2024<br>| 35 | 38 |
| Additional paid-in capital | 2060114 | 2165633 |
| Accumulated deficit | (1417118) | (1441013) |
| Total stockholders' equity | 643031 | 724658 |
| Total liabilities and stockholders' equity | $1318706 | $1388067 |

---

*See accompanying notes to condensed consolidated financial statements.*

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**GoodRx Holdings, Inc.**

**Condensed Consolidated Statements of Operations**

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br>**June 30,** | **Three Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(in thousands, except for per share amounts)* | **2025** | **2024** | **2025** | **2024** |
| Revenue | $203070 | $200610 | $406040 | $398490 |
| Costs and operating expenses: |  |  |  |  |
| Cost of revenue, exclusive of depreciation and <br>amortization presented separately below<br>| 13350 | 11870 | 26714 | 24338 |
| Product development and technology | 29933 | 30854 | 61075 | 61871 |
| Sales and marketing | 84870 | 93454 | 169412 | 183418 |
| General and administrative | 28379 | 27589 | 58009 | 68697 |
| Depreciation and amortization | 19729 | 16965 | 40641 | 32907 |
| Total costs and operating expenses | 176261 | 180732 | 355851 | 371231 |
| Operating income | 26809 | 19878 | 50189 | 27259 |
| Other expense, net: |  |  |  |  |
| Other income | 694 |  | 694 |  |
| Interest income | 2803 | 6334 | 6735 | 13889 |
| Interest expense | (10729) | (14566) | (21373) | (29209) |
| Total other expense, net | (7232) | (8232) | (13944) | (15320) |
| Income before income taxes | 19577 | 11646 | 36245 | 11939 |
| Income tax expense | (6734) | (4952) | (12350) | (6254) |
| Net income | $12843 | $6694 | $23895 | $5685 |
| **Earnings per share:** |  |  |  |  |
| Basic | $0.04 | $0.02 | $0.06 | $0.01 |
| Diluted | $0.04 | $0.02 | $0.06 | $0.01 |
| **Weighted average shares used in computing** <br>**earnings per share:**<br>|  |  |  |  |
| Basic | 356623 | 376254 | 367847 | 386153 |
| Diluted | 357159 | 384732 | 368345 | 393620 |
| **Stock-based compensation included in costs and** <br>**operating expenses:**<br>|  |  |  |  |
| Cost of revenue | $122 | $64 | $222 | $140 |
| Product development and technology | 6323 | 6259 | 11993 | 12107 |
| Sales and marketing | 5929 | 9396 | 11811 | 17523 |
| General and administrative | 9041 | 10871 | 16563 | 21916 |

---

*See accompanying notes to condensed consolidated financial statements.*

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**GoodRx Holdings, Inc.**

**Condensed Consolidated Statements of Stockholders' Equity**

*(Unaudited)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A and Class B**<br>**Common Stock** | **Class A and Class B**<br>**Common Stock** | **Additional**<br>**Paid-in** <br>**Capital**  | **Accumulated** <br>**Deficit**  | **Total**<br>**Stockholders'** <br>**Equity**  |
| *(in thousands)* | **Shares**  | **Amount** | **Additional**<br>**Paid-in** <br>**Capital**  | **Accumulated** <br>**Deficit**  | **Total**<br>**Stockholders'** <br>**Equity**  |
| Balance at December 31, 2024 | 382815 | $38 | $2165633 | $(1441013) | $724658 |
| Stock options exercised | 4 |  | 2 |  | 2 |
| Stock-based compensation |  |  | 23312 |  | 23312 |
| Vesting and settlement of restricted stock <br>units<br>| 2136 |  |  |  |  |
| Common stock withheld related to net <br>share settlement<br>| (802) |  | (3757) |  | (3757) |
| Repurchases of Class A common stock <sup>(1)</sup> | (23340) | (2) | (100918) |  | (100920) |
| Net income |  |  |  | 11052 | 11052 |
| Balance at March 31, 2025 | 360813 | $36 | $2084272 | $(1429961) | $654347 |
| Stock options exercised | 2 |  | 1 |  | 1 |
| Stock-based compensation |  |  | 25880 |  | 25880 |
| Vesting and settlement of restricted stock <br>units<br>| 3014 |  |  |  |  |
| Common stock withheld related to net <br>share settlement<br>| (1056) |  | (4548) |  | (4548) |
| Repurchases of Class A common stock | (10224) | (1) | (46351) |  | (46352) |
| Issuance of common stock through <br>employee stock purchase plan<br>| 222 |  | 860 |  | 860 |
| Net income |  |  |  | 12843 | 12843 |
| Balance at June 30, 2025 | 352771 | $35 | $2060114 | $(1417118) | $643031 |

---

*See accompanying notes to condensed consolidated financial statements.*

_____________________________________________________

(1)Repurchases of Class A common stock for the three months ended March 31, 2025 include 20.0 million shares

repurchased from related parties (after giving effect to the automatic conversion of Class B common stock to Class

A common stock upon such repurchase) for an aggregate consideration of $84.9 million. See "Note 10.

Stockholders' Equity" for additional information.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**GoodRx Holdings, Inc.**

**Condensed Consolidated Statements of Stockholders' Equity**

*(Unaudited)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A and Class B**<br>**Common Stock** | **Class A and Class B**<br>**Common Stock** | **Additional**<br>**Paid-in** <br>**Capital** | **Accumulated** <br>**Deficit** | **Total**<br>**Stockholders'** <br>**Equity** |
| *(in thousands)* | **Shares**  | **Amount** | **Additional**<br>**Paid-in** <br>**Capital** | **Accumulated** <br>**Deficit** | **Total**<br>**Stockholders'** <br>**Equity** |
| Balance at December 31, 2023 | 394087 | $40 | $2219321 | $(1457403) | $761958 |
| Stock options exercised | 604 |  | 2666 |  | 2666 |
| Stock-based compensation |  |  | 28891 |  | 28891 |
| Vesting and settlement of restricted stock <br>units<br>| 2535 |  |  |  |  |
| Common stock withheld related to net <br>share settlement<br>| (954) |  | (6623) |  | (6623) |
| Repurchases of Class A common stock <sup>(1)</sup> | (21329) | (2) | (154812) |  | (154814) |
| Net loss |  |  |  | (1009) | (1009) |
| Balance at March 31, 2024 | 374943 | $38 | $2089443 | $(1458412) | $631069 |
| Stock options exercised | 1454 |  | 8947 |  | 8947 |
| Stock-based compensation |  |  | 30885 |  | 30885 |
| Vesting and settlement of restricted stock <br>units<br>| 3262 |  |  |  |  |
| Common stock withheld related to net <br>share settlement<br>| (1231) |  | (9343) |  | (9343) |
| Repurchases of Class A common stock |  |  | 290 |  | 290 |
| Issuance of common stock through <br>employee stock purchase plan<br>| 179 |  | 857 |  | 857 |
| Net income |  |  |  | 6694 | 6694 |
| Balance at June 30, 2024 | 378607 | $38 | $2121079 | $(1451718) | $669399 |

---

*See accompanying notes to condensed consolidated financial statements.*

_____________________________________________________

(1)Repurchases of Class A common stock for the three months ended March 31, 2024 include 20.9 million shares

repurchased from related parties (after giving effect to the automatic conversion of Class B common stock to Class

A common stock upon such repurchase) for an aggregate consideration of $151.4 million. See "Note 10.

Stockholders' Equity" for additional information.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**GoodRx Holdings, Inc.**

**Condensed Consolidated Statements of Cash Flows**

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(in thousands)* | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net income | $23895 | $5685 |
| Adjustments to reconcile net income to net cash provided by operating <br>activities:<br>|  |  |
| Depreciation and amortization | 40641 | 32907 |
| Amortization of debt issuance costs and discounts | 869 | 1663 |
| Non-cash operating lease expense | 2065 | 1930 |
| Stock-based compensation expense | 40589 | 51686 |
| Loss on operating lease asset | 4409 |  |
| Other | 456 |  |
| Changes in operating assets and liabilities: |  |  |
| Accounts receivable | (43093) | (18166) |
| Prepaid expenses and other assets | (15796) | (5981) |
| Accounts payable | 11086 | (18017) |
| Accrued expenses and other current liabilities | (3235) | 1973 |
| Operating lease liabilities | (3187) | (1770) |
| Other liabilities | 294 | 377 |
| Net cash provided by operating activities | 58993 | 52287 |
| **Cash flows from investing activities** |  |  |
| Purchase of property and equipment | (532) | (675) |
| Acquisition | (30000) |  |
| Capitalized software | (39659) | (37169) |
| Net cash used in investing activities | (70191) | (37844) |
| **Cash flows from financing activities** |  |  |
| Payments on long-term debt | (2500) | (5273) |
| Repurchases of Class A common stock <sup>(1)</sup> | (145888) | (153226) |
| Proceeds from exercise of stock options | 3 | 11772 |
| Employee taxes paid related to net share settlement of equity awards | (8305) | (15966) |
| Proceeds from employee stock purchase plan | 860 | 857 |
| Net cash used in financing activities | (155830) | (161836) |
| Net change in cash and cash equivalents | (167028) | (147393) |
| Cash and cash equivalents |  |  |
| Beginning of period | 448346 | 672296 |
| End of period | $281318 | $524903 |
| **Supplemental disclosure of cash flow information** |  |  |
| Non cash investing and financing activities: |  |  |
| Right-of-use assets obtained in exchange for operating lease liabilities | $9098 | $1894 |
| Stock-based compensation included in capitalized software | 8603 | 8090 |
| Capitalized software included in accounts payable and accrued expenses and <br>other current liabilities<br>| 6645 | 4628 |

---

*See accompanying notes to condensed consolidated financial statements.*

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

_____________________________________________________

(1)Repurchases of Class A common stock for the six months ended June 30, 2025 and 2024 include 20.0 million and

20.9 millionshares repurchased from related parties (after giving effect to the automatic conversion of Class B

common stock to Class A common stock upon such repurchase) for an aggregate consideration of $84.9 million

and $151.4 million, respectively. See "Note 10. Stockholders' Equity" for additional information.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**GoodRx Holdings, Inc.**

**Notes to Condensed Consolidated Financial Statements**

*(Unaudited)*

**1. Description of Business**

GoodRx Holdings, Inc. was incorporated in September 2015 and has no material assets or standalone operations other

than its ownership in its consolidated subsidiaries. GoodRx, Inc. ("GoodRx"), a Delaware corporation initially formed in

September 2011, is a wholly-owned subsidiary of GoodRx Intermediate Holdings, LLC, which itself is a wholly-owned

subsidiary of GoodRx Holdings, Inc.

GoodRx Holdings, Inc. and its subsidiaries (collectively, "we," "us" or "our") offer information and tools to help

consumers compare prices and save on their prescription drug purchases. We operate a price comparison platform that

provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices

through our codes that can be used to save money on prescriptions across the United States ("prescription transactions

offering"). We also offer other healthcare products and services, including subscription programs, pharmaceutical ("pharma")

manufacturer solutions and telehealth services.

**2. Summary of Significant Accounting Policies**

**Basis of Presentation**

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with

accounting principles generally accepted in the United States ("GAAP") and applicable rules and regulations of the

Securities and Exchange Commission ("SEC") regarding interim financial information. Certain information and disclosures

normally included in our annual consolidated financial statements prepared in accordance with GAAP have been condensed

or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with our audited

consolidated financial statements for the year ended December 31, 2024 and the related notes, which are included in our

Annual Report on Form 10-K filed with the SEC on February 27, 2025 ("2024 10-K"). The December 31, 2024 condensed

consolidated balance sheet was derived from our audited consolidated financial statements as of that date. The condensed

consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring

items, necessary for the fair statement of our condensed consolidated financial statements. The operating results for the

three and six months ended June 30, 2025 are not necessarily indicative of the results expected for the full year ending

December 31, 2025.

There have been no material changes in significant accounting policies during the three and six months ended June 30,

2025 from those disclosed in "Note 2. Summary of Significant Accounting Policies" in the notes to our consolidated financial

statements included in our 2024 10-K.

**Principles of Consolidation**

The condensed consolidated financial statements include the accounts of GoodRx Holdings, Inc., its wholly owned

subsidiaries and variable interest entities for which we are the primary beneficiary. Intercompany balances and transactions

have been eliminated in consolidation. Results of businesses acquired are included in our condensed consolidated financial

statements from their respective dates of acquisition.

**Segment Reporting**

Operating segments are defined as components of an enterprise for which separate financial information is available

that is regularly provided to the chief operating decision maker ("CODM") in deciding how to allocate resources and in

assessing performance. Our CODM manages our business on the basis of one operating segment.

Our operating segment derives revenue in a manner as disclosed in "Note 2. Summary of Significant Accounting

Policies" in the notes to our consolidated financial statements included in our 2024 10-K. Our CODM is our principal

executive officer, who is our Chief Executive Officer and President beginning in 2025. Consolidated net income or loss is the

measure of segment profit or loss reviewed by our CODM in assessing segment performance and deciding how to allocate

resources. Our CODM uses consolidated net income or loss to monitor budget versus actual results, review historical

company performance trends, conduct benchmark analysis of our peers and competitors, and evaluate management's

compensation. Significant expenses included in the reported measure of segment profit or loss are provided to our CODM

on a consolidated basis as presented in the accompanying condensed consolidated statements of operations.

**Use of Estimates**

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to

make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements,

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

including the accompanying notes. We base our estimates on historical factors; current circumstances; macroeconomic

events and conditions; and the experience and judgment of our management. We evaluate our estimates and assumptions

on an ongoing basis. Actual results can differ materially from these estimates, and such differences can affect the results of

operations reported in future periods.

**Certain Risks and Concentrations**

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash,

cash equivalents and accounts receivable.

We maintain cash deposits with multiple financial institutions in the United States which, at times, may exceed federally

insured limits. Cash may be withdrawn or redeemed on demand. We believe that the financial institutions that hold our cash

are financially sound and, accordingly, minimal credit risk exists with respect to these balances. However, market conditions

can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our

cash and cash equivalents, there can be no assurance that we will be able to access uninsured funds in a timely manner or

at all. We have not experienced any losses in such accounts.

We consider all short-term, highly liquid investments purchased with an original maturity of three months or less at the

date of purchase to be cash equivalents. Cash equivalents, consisting of U.S. treasury securities money market funds, of

$261.0 million and $405.0 million at June 30, 2025 and December 31, 2024, respectively, were classified as Level 1 of the

fair value hierarchy and valued using quoted market prices in active markets.

We extend credit to our customers based on an evaluation of their ability to pay amounts due under contractual

arrangements and generally do not obtain or require collateral. For each of the three and six months ended June 30, 2025,

one customer accounted for 12% of our revenue. For each of the three and six months ended June 30, 2024, one customer

accounted for 11% of our revenue. At June 30, 2025 and December 31, 2024, no customer accounted for more than 10% of

our accounts receivable balance.

**Equity Investments**

We retain minority equity interests in privately-held companies without readily determinable fair values. Our ownership

interests are less than 20% of the voting stock of the investees and we do not have the ability to exercise significant

influence over the operating and financial policies of the investees. The equity investments are accounted for under the

measurement alternative in accordance with Accounting Standards Codification ("ASC") 321, *Investments – Equity*

*Securities*, which is cost minus impairment, if any, plus or minus changes resulting from observable price changes. We did

not recognize any changes resulting from observable price changes or impairment losses on our minority equity interest

investments during the three and six months ended June 30, 2025 and 2024. Equity investments included in other assets on

our condensed consolidated balance sheets were $15.0 million as of June 30, 2025 and December 31, 2024.

**Impairment of Long-Lived Assets**

We account for the impairment of long-lived assets in accordance with ASC 360, *Property, Plant, and Equipment*. In

accordance with ASC 360, long-lived assets to be held and used are reviewed for impairment when events or changes in

circumstances indicate that their carrying values may not be recoverable. We perform impairment testing at the asset group

level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other

assets and liabilities. An impairment loss is recognized when estimated undiscounted future cash flows expected to result

from the use of the asset and its eventual disposition are less than its carrying value. If an asset is determined to be

impaired, the impairment is measured by the amount that the carrying value of the asset exceeds its fair value.

During the three months ended March 31, 2025, we recognized an impairment loss of $4.4 million within general and

administrative expenses to reduce the carrying value of an asset group to its estimated fair value of $3.4 million. The asset

group was comprised of an operating lease right-of-use asset and related improvements that we had determined to

sublease in 2022. The facts and circumstances leading to the impairment were primarily based on a recently submitted

sublease proposal which indicated a significant deterioration in the sublease market and rental rates whereby the carrying

value of the asset group may not be recoverable. The estimated fair value was determined by using a discounted cash flow

method which is a non-recurring fair value measurement based on Level 3 inputs. Key inputs used in this estimate included

projected sublease income and a discount rate which incorporated the risk of achievement associated with the forecast. We

otherwise have not recognized any impairment losses of our long-lived assets during the three and six months ended June

30, 2025 and 2024.

**Recent AccountingPronouncements**

In July 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")

2025-05, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and*

*Contract Assets for Private Companies and Certain Not-For-Profit Entities.* This ASU amends ASC 326-20 in part to provide

a practical expedient election to assume that current conditions as of the balance sheet date do not change for the

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

remaining life of current accounts receivable and/or current contract assets arising from transactions accounted for under

Topic 606, *Revenue from Contracts with Customers*. This ASU will be effective for all entities for annual reporting periods

beginning after December 15, 2025, and for interim reporting periods within those annual reporting periods. Early adoption

of this ASU is permitted and should be applied prospectively. We are currently evaluating the impact of the adoption of this

ASU on our consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income - Expense*

*Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*, which is intended to improve

the disclosures of expenses by providing more detailed information about the types of expenses in commonly presented

expense captions. This ASU requires entities to disclose the amounts of purchases of inventory, employee compensation,

depreciation and intangible asset amortization included in each relevant expense caption; as well as a qualitative description

of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. This ASU also

requires disclosure of the total amount of selling expense and, in annual reporting periods, an entity's definition of selling

expenses. In January 2025, the FASB issued ASU 2025-01 which clarified the effective date of this ASU. This ASU applies

to all public entities and will be effective for fiscal years beginning after December 15, 2026, and for interim periods within

fiscal years beginning after December 15, 2027. Early adoption of this ASU is permitted. This ASU should be applied either

prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any

or all prior periods presented in the financial statements. We are currently evaluating the impact of the adoption of this ASU

on our consolidated financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax*

*Disclosures*. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The

amendments in this ASU address investor requests for enhanced income tax information primarily through changes to the

rate reconciliation and income taxes paid information. This ASU applies to all public entities and will be effective for fiscal

years beginning after December 15, 2024, and for interim periods for fiscal years beginning after December 15, 2025. Early

adoption of this ASU is permitted. The disclosure requirements can be applied either on a prospective or retrospective basis.

We are currently evaluating the impact of the adoption of this ASU on our consolidated financial statement disclosures, but

expect the adoption of this pronouncement will lead to additional income tax disclosures in our consolidated financial

statements for 2025 and future annual periods.We plan to apply the disclosure requirements on a retrospective basis upon

adoption.

**3. Business Combination**

On January 13, 2025, we acquired substantially all of the assets and assembled workforce of VCRx, a prescription

savings business of Vivid Clear Rx, Inc., for $30.0 million in cash. VCRx operates a price comparison platform that provides

consumer prescription savings through its partnership with PBMs. The acquisition expands our consumer reach particularly

with respect to our prescription transactions offering.

Goodwill associated with this acquisition totaled $11.0 million and primarily related to the expected long-term synergies

and other benefits, including the acquired assembled workforce. The goodwill is deductible for tax purposes. Identifiable

intangible assets related to this acquisition, totaled $19.0 million, of which $18.1 million was attributable to a customer

related intangible asset, with an estimated useful life of 6 years.

Unaudited supplemental pro forma financial information, revenue and earnings from the date of acquisition, and

transaction costs related to the VCRx acquisition have not been presented because the effects are not material to our

condensed consolidated financial statements.

**4. Prepaid Expenses and Other Current Assets**

Prepaid expenses and other current assets consist of the following:

---

| | | |
|:---|:---|:---|
| *(in thousands)* | **June 30, 2025** | **December 31, 2024** |
| Insurance recovery receivable<sup>(1)</sup> | $11900 | $14900 |
| Income taxes receivable | 1379 |  |
| Reimbursable third-party payments <sup>(2)</sup> | 38971 | 22944 |
| Other prepaid expenses and other current assets <sup>(3)</sup> | 28019 | 27131 |
| Total prepaid expenses and other current assets | $80269 | $64975 |

---

_____________________________________________________

(1)Represents a receivable for the probable recovery related to an incurred loss in connection with certain

contingencies. Loss recoveries are recognized when a loss has been incurred and the recovery is probable. This

determination is based on our analysis of the underlying insurance policies, historical experience with insurers, and

ongoing review of the solvency of insurers, among other factors.

(2)Represents payments we make to third parties on behalf of, and reimbursable from, certain customers.

(3)Other current assets were not material as of June 30, 2025 and December 31, 2024.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**5. Accrued Expenses and Other Current Liabilities**

Accrued expenses and other current liabilities consist of the following:

---

| | | |
|:---|:---|:---|
| *(in thousands)* | **June 30, 2025** | **December 31, 2024** |
| Accrued bonus and other payroll related | $20749 | $28260 |
| Accrued legal settlement | 25355 | 25000 |
| Accrued marketing | 13245 | 14311 |
| Income taxes payable | 11874 | 1457 |
| Reimbursable liabilities <sup>(1)</sup> | 6978 | 15798 |
| Deferred revenue | 6076 | 6036 |
| Other accrued expenses | 11400 | 8268 |
| Total accrued expenses and other current liabilities | $95677 | $99130 |

---

_____________________________________________________

(1)Represents amounts owed to third parties on behalf of, and reimbursable from, certain customers.

Deferred revenue represents payments received in advance of providing services for certain advertising contracts with

customers and subscriptions. We expect substantially all of the deferred revenue at June 30, 2025 will be recognized as

revenue within the subsequent twelve months. Of the $6.0 million of deferred revenue at December 31, 2024, $0.9 million

and $5.2 million was recognized as revenue during the three and six months ended June 30, 2025, respectively. Revenue

recognized during the three and six months ended June 30, 2024 of $1.0 million and $6.4 million, respectively, was included

as deferred revenue at December 31, 2023.

**6. Income Taxes**

We generally calculate income taxes in interim periods by applying an estimated annual effective income tax rate to

income or loss before income taxes and by calculating the tax effect of discrete items recognized during such periods. Our

estimated annual effective income tax rate is based on our estimated full year income or loss and the related income taxes

for each jurisdiction in which we operate. This rate can be affected by estimates of full year pre-tax income or loss and

permanent differences.

The effective income tax rate for the three months ended June 30, 2025 and 2024 was 34.4% and 42.5%, respectively.

The effective income tax rate for the six months ended June 30, 2025 and 2024 was 34.1% and 52.4%, respectively. The

primary differences between our effective income tax rates and the federal statutory tax rate for the three and six months

ended June 30, 2025 and 2024 were due to the effects of non-deductible officers' stock-based compensation expense, state

income taxes, benefits from research and development tax credits, and tax effects from our equity awards.

On July 4, 2025, H.R. 1, titled "A bill to provide for reconciliation pursuant to Title II of H. Con. Res. 14," commonly

referred to as the One Big Beautiful Bill Act ("OBBBA") was enacted. The OBBBA contains several changes to corporate

taxation including modifications to capitalization of research and development expenses, limitations on deductions for

interest expense and accelerated fixed asset depreciation. We are currently evaluating the provisions of the OBBBA and the

effects on our consolidated financial statements. The effects of changes in tax rates and laws are recognized in the period of

enactment. As the OBBBA was signed into law after the close of our second fiscal quarter, the impacts are not included in

our condensed consolidated financial statements for the three and six months ended June 30, 2025 and will be included in

our condensed consolidated financial statements for the three and nine months ending September 30, 2025.

**7. Debt**

Our First Lien Credit Agreement (as amended from time to time, the "Credit Agreement") provides for (i) a $500.0 million

term loan maturing on July 10, 2029 ("2024 Term Loan Facility"); and (ii) a revolving credit facility for up to $100.0 million

(the "Revolving Credit Facility") of which $12.0 million matured on July 11, 2025 and the remaining $88.0 million will mature

on April 10, 2029. As of June 30, 2025, there were no changes to the terms of our 2024 Term Loan Facility and Revolving

Credit Facility as disclosed in Note 12 to our consolidated financial statements included in our 2024 10-K.

The effective interest rate on our term loans for the three months ended June 30, 2025 and 2024 was 8.60% and

8.75%, respectively. The effective interest rate on our term loans for the six months ended June 30, 2025 and 2024 was

8.56% and 8.76%, respectively.

We had no borrowings against the Revolving Credit Facility as of June 30, 2025 and December 31, 2024.

We had outstanding letters of credit issued against the Revolving Credit Facility for $7.8 million and $8.3 million as of

June 30, 2025 and December 31, 2024, respectively, which reduce our available borrowings under the Revolving Credit

Facility.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

Our debt balance is as follows:

---

| | | |
|:---|:---|:---|
| *(in thousands)* | **June 30, 2025** | **December 31, 2024** |
| Principal balance under 2024 Term Loan Facility | $497500 | $500000 |
| Less: Unamortized debt issuance costs and discounts | (7528) | (8289) |
|  | $489972 | $491711 |

---

The estimated fair value of our debt approximated its carrying value as of June 30, 2025 and December 31, 2024,

based on inputs categorized as Level 2 in the fair value hierarchy.

Under the Credit Agreement, we are subject to a financial covenant requiring maintenance of a First Lien Net Leverage

Ratio (as defined in the Credit Agreement) not to exceed 8.2 to 1.0 only in the event that the amounts outstanding under the

Revolving Credit Facility exceed a specified percentage of commitments under the Revolving Credit Facility, and other

nonfinancial covenants under the Credit Agreement. At June 30, 2025, we were in compliance with our covenants under the

Credit Agreement.

**8. Commitments and Contingencies**

As of June 30, 2025, apart from the lease agreement discussed below, there were no material changes to our

commitments and contingencies as disclosed in the notes to our consolidated financial statements included in our 2024 10-

K. **Leases**

On April 16, 2025, we entered into a non-cancellable office lease agreement in New York, New York that extended the

lease term of an existing space and provided for a new space, both of which end in early 2036. The total future minimum

lease payments are approximately $14.7 million.

**Legal Contingencies**

*Consumer privacy class action* - Between February 2, 2023, and March 30, 2023, five individual plaintiffs filed five

separate putative class actions lawsuits against Google, Meta, Criteo and us, alleging generally that we have not adequately

protected consumer privacy and that we communicated consumer information to third parties, including the three co-

defendants. Four of the plaintiffs allege common law intrusion upon seclusion and unjust enrichment claims, as well as

claims under California's Confidentiality of Medical Information Act, Invasion of Privacy Act, Consumer Legal Remedies Act,

and Unfair Competition Law. One of these four plaintiffs additionally brings a claim under the Electronic Communications

Privacy Act. The fifth plaintiff brings claims for common-law unjust enrichment and violations of New York's General

Business Law. Four of these cases were originally filed in the United States District Court for the Northern District of

California ("NDCA) (Cases No. 3:23-cv-00501; 3:23-cv-00744; 3:23-cv-00940; and 4:23-cv-01293). One case was originally

filed in the United States District Court for the Southern District of New York (Case No. 1:23-cv-00943); however, that case

was voluntarily dismissed and re-filed in the NDCA (Case No. 3:23-cv-01508). These five matters have been consolidated

and assigned to U.S. District Judge Araceli Martínez-Olguín in the NDCA. The court also set a briefing schedule for filing a

single consolidated complaint, which the plaintiffs filed on May 21, 2023 (Case No. 3:23-cv-00501-AMO; the "NDCA Class

Action Matter"), as well as motions to dismiss and motions to compel arbitration. In addition to the aforementioned claims,

the plaintiffs in the now consolidated matter bring claims under the Illinois Consumer Fraud and Deceptive Business

Practices Act, common law negligence and negligence per se, in each case, pleaded in the alternative. The plaintiffs are

seeking various forms of monetary damages (such as statutory damages, compensatory damages, attorneys' fees and

disgorgement of profits) as well as injunctive relief. Briefing on the motions to dismiss and motions to compel arbitration was

completed on August 24, 2023.

On October 27, 2023, six plaintiffs filed a class action complaint (Case No. 1:23-cv-24127-BB; the "SDFL Class Action

Matter") against us in the United States District Court for the Southern District of Florida ("SDFL"). The plaintiffs alleged, on

behalf of the same nationwide class as the NDCA Class Action Matter, substantially the same statutory and common law

violation claims as alleged in that matter as well as claims based on the federal Electronic Communications Privacy Act,

invasion of privacy under California common law and the California constitution, invasion of privacy under New Jersey's

Constitution, and violations of Pennsylvania's Wiretapping and Electronic Surveillance Control Act, Florida's Security of

Communications Act, New York's Civil Rights Law and Stop Hack and Improve Electronic Data Security Act. The plaintiffs in

the SDFL Class Action Matter seek various forms of monetary damages as well as injunctive and other unspecified equitable

relief.

On October 27, 2023, we entered into a proposed settlement agreement with the plaintiffs in the SDFL Class Action

Matter, on behalf of a nationwide settlement class that includes the NDCA Class Action Matter, which provides for a payment

of $13.0 million by us. On October 30, 2023, the plaintiffs in the SDFL Class Action Matter filed a motion and memorandum

in support of preliminary approval of the proposed class action settlement and, on October 31, 2023, the SDFL granted

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

preliminary approval of the proposed settlement. The proposed settlement is subject to final approval of the court. Members

of the class have the opportunity to opt-out of the class and commence their own actions.

In response to the proposed settlement in the SDFL Class Action Matter, plaintiffs in the NDCA Class Action Matter filed

(i) on November 1, 2023, a motion in the NDCA for an order to require us to cease litigation of, or alternatively file a motion

to stay in, the SDFL Class Action Matter and enjoin us from seeking settlement with counsel other than plaintiffs' counsel in

the NDCA Class Action Matter; and (ii) on November 2, 2023, a motion in the SDFL for that court to allow them to intervene

and appear in the SDFL action, transfer the SDFL Class Action Matter to the NDCA and reconsider and deny its preliminary

approval of the proposed settlement. The SDFL has issued an order requiring the SDFL plaintiffs to, among other things, file

a response to the NDCA plaintiffs' motion to intervene. Additionally, U.S. District Judge Araceli Martínez-Olguín in the NDCA

issued an order for us to show cause as to why we should not be sanctioned for an alleged failure to provide notification to

the NDCA of the pendency of the SDFL Class Action Matter. We filed our written response to this order on November 8,

2023. The NDCA held a hearing on November 14, 2023, and ordered parties to the litigation to participate in mediation. The

parties participated in mediation on January 10, 2024, and agreed to participate in an additional day of mediation, which

occurred on March 7, 2024.

On December 3, 2024, the SDFL plaintiffs filed a voluntary motion to dismiss, with prejudice, which was approved by

the court on December 4, 2024. On November 25, 2024, we entered into a settlement agreement, with the NDCA plaintiffs

for $25.0 million, subject to approval by the court. On June 12, 2025, the court denied the motion for preliminary approval of

the settlement with prejudice, with leave for the plaintiffs to refile with additional information requested by the court. Based

on the settlement agreement, an estimated probable loss of $25.0 million was recognized within accrued expenses and

other current liabilities on our consolidated balance sheet as of December 31, 2024, and remained accrued as of June 30,

2025. While this amount represents our best judgment of the probable loss based on the information currently available to

us, it is subject to significant judgments and estimates and numerous factors beyond our control, including, without limitation,

final approval of the court. In addition, while it is reasonably possible an incremental loss may have been incurred for the

indemnification of certain parties named in the class action lawsuits, a loss, or a range of loss, is not reasonably estimable.

The results of legal proceedings are inherently uncertain, and upon final resolution of these matters, it is reasonably possible

that the actual loss may differ from our estimate.

*Securities class action & derivative lawsuits* - On April 22, 2024, Lisa Marie Barsuli, individually and on behalf of all

others similarly situated, filed a class action lawsuit against us and certain of our executive officers in the United States

District Court for the Central District of California (Case No. 2:24-cv-3282). The plaintiffs seek compensatory damages and

equitable relief as well as interest, fees and costs. The complaint alleges violations of Sections 10(b) and 20(a) of the

Exchange Act and Rule 10b-5 promulgated thereunder, and asserts that we and certain of our executive officers failed to

disclose to investors the risk relating to a grocery chain taking actions that impacted acceptance of our discounted pricing for

a subset of prescription drugs from PBMs, whose pricing we promote on our platform (the "grocer issue"), which occurred

late in the first quarter of 2022. As alleged in the complaint, when we disclosed the occurrence of the grocer issue, our stock

price fell, causing investor losses. On July 25, 2024, U.S. District Judge André Birotte Jr. appointed The Kalmanson Family

as the lead plaintiff and approved selection of lead plaintiff's counsel. We filed a motion to dismiss the class action lawsuit on

November 19, 2024. On January 10, 2025, the plaintiffs filed their opposition to our motion to dismiss, and we filed our

response on February 11, 2025.

Additionally, on various dates between May 23, 2024 and November 6, 2024, alleged stockholders Benjamin Solomon

(Case No. 2:24-cv-04301), Joseph Caetano (Case No. 2:24-cv-06993), Colby Mayes (Case No. 2:24-cv-07264), Sharon

Burgs (Case No. 2:24-cv-07281), and Stephen Bushansky (Case No. 2:24-cv-09611) each filed separate derivative lawsuits

in the United States District Court for the Central District of California, in each case, purportedly on behalf of us against

certain of our current and former executive officers and directors. The derivative complaints assert various claims, including

for violations of, and contribution under, the Exchange Act, breach of fiduciary duty, unjust enrichment, abuse of control,

gross mismanagement, corporate waste and violations of insider trading laws. The claims in each of these derivative

lawsuits are based on allegations substantially similar to those in the class action lawsuit described above and also allege

that we failed to maintain adequate internal controls. The plaintiffs in these derivative lawsuits are seeking declaratory relief,

monetary damages, restitution, disgorgement of alleged illegal profits and/or certain governance reforms. On December 20,

2024, plaintiffs in the derivative lawsuits agreed to consolidate the cases and stay the action pending the resolution of the

securities class action's motion to dismiss. On February 20, 2025, the court granted the stipulation and consolidated the

cases under Case No. 2:24-cv-04301-AB-JPR.

On April 23, 2025, the court granted our motion to dismiss the securities class action lawsuit, without prejudice and with

leave to amend.

*Consumer state litigations* - On May 28, 2024, The Bert and Annette Mullens Foundation filed a lawsuit against us in

Pope County, Arkansas, alleging that we violated an Arkansas statute related to the distribution of health-related discount

cards. Specifically, the statute provides that each discount card must "expressly provide in bold and prominent type that the

discounts are not insurance." Ark. Code Ann. § 4-106-201(1). Furthermore, the statute provides that each card must

"expressly provide in bold and prominent type on the card or in a statement attached to the card that the consumer has the

right to cancel his or her registration within thirty (30) days from the effective date of the card." Ark. Code Ann. §

4-106-201(2). The plaintiff alleges that our cards did not comply with these requirements, and sought an injunction and

statutory damages. We filed a motion to dismiss the complaint, which was denied on December 2, 2024. On May 9, 2025,

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

the Arkansas Attorney General moved to intervene in the case. On May 13, 2025, the plaintiff moved for partial summary

judgment, which we and the Arkansas Attorney General opposed. Furthermore, on June 11, 2024, the Minnesota Teamsters

Service Bureau, also filed a lawsuit against us in Hennepin County, Minnesota, alleging that we violated a Minnesota statute

related to the distribution of health-related discount cards. Specifically, the statute provides that each discount card must

"expressly provide in bold and prominent type that the discounts are not insurance." Minn. Stat. Ann. § 325F.784, subd. 1(1).

The plaintiff alleges that our cards do not comply with these requirements and also seeks an injunction and statutory

damages. We filed a motion to dismiss the complaint, which was denied on December 17, 2024. On June 10, 2025, the

plaintiff moved to dismiss some of our counterclaims. Discovery is ongoing in both matters.

We intend to vigorously defend against the claims asserted in the securities class action, derivative lawsuits, and

consumer state litigations. We believe we have meritorious defenses to such claims and based upon information presently

known to management, we have not accrued a loss for the securities class action and derivative lawsuits as a loss is not

probable nor reasonably estimable. While it is reasonably possible a loss may have been incurred, we are unable to

estimate a loss or range of loss in these matters. Relating to the consumer state litigations, the estimated probable loss as of

June 30, 2025 was not material and represents our best judgment based on the information currently available to us.

These pending proceedings involve complex questions of fact and law and may require the expenditure of significant

funds and the diversion of other resources to defend. In addition, during the normal course of business, we (including our

directors and officers whom we indemnify) may become subject to, and are presently involved in, legal proceedings, claims

and litigation. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. We have

not accrued for a loss for any other matters as a loss is not probable and a loss, or a range of loss, is not reasonably

estimable. Accruals for loss contingencies are recognized when a loss is probable, and the amount of such loss can be

reasonably estimated. See "Note 5. Accrued Expenses and Other Current Liabilities" for additional information. Loss

recoveries are recognized when a loss has been incurred and the recovery is probable. See "Note 4. Prepaid Expenses and

Other Current Assets" for additional information.

*GoodRx as plaintiff in arbitration award -* In February 2023, we initiated arbitration against Famulus Health, LLC

("Famulus") before the American Arbitration Association in relation to Famulus' breach of an agreement entered into by

Famulus and us in June 2020, as amended (the "Agreement"). We asserted claims for Famulus' breach of the confidentiality

and exclusivity provisions in the Agreement, seeking to recover damages and injunctive relief. On February 15, 2024, an

arbitration award was rendered, which included a damages award and a permanent injunction (the "Arbitration Award").

Famulus filed a petition to vacate the Arbitration Award on February 21, 2024 in the United States District Court for the

District of South Carolina ("DSC"). We filed a petition to confirm the Arbitration Award on February 22, 2024 in the DSC. In

April 2024, several motions and oppositions were filed, which were consolidated by the DSC on April 12, 2024. On

September 11, 2024, the DSC entered an opinion and order denying Famulus's motion to vacate the Arbitration Award and

granting our motion to confirm the Arbitration Award as modified by the DSC. On October 11, 2024, we filed an application

for writ of execution in the DSC, which was issued on October 16, 2024. The writ directs a U.S. Marshal of the District of

South Carolina to levy Famulus's property in execution of our judgment. We cannot make any assurance as to the outcome

of the Arbitration Award or if the Arbitration Award will be collected. Any gain on this matter is considered a gain contingency

and will be recognized in the period in which the Arbitration Award is realized or realizable, pursuant to ASC 450,

*Contingencies.*

**9. Revenue**

For the three and six months ended June 30, 2025 and 2024, revenue comprised the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br>**June 30,** | **Three Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(in thousands)* | **2025** | **2024** | **2025** | **2024** |
| Prescription transactions revenue | $143064 | $146748 | $291987 | $292143 |
| Subscription revenue | 20463 | 21953 | 41480 | 44554 |
| Pharma manufacturer solutions revenue | 34981 | 26504 | 63629 | 51013 |
| Other revenue | 4562 | 5405 | 8944 | 10780 |
| Total revenue | $203070 | $200610 | $406040 | $398490 |

---

**10. Stockholders' Equity**

On February 23, 2022, our board of directors ("Board") authorized the repurchase of up to an aggregate of

$250.0 million of our Class A common stock through February 23, 2024. On February 27, 2024, our Board approved a new

stock repurchase program which authorized the repurchase of up to an aggregate of $450.0 million of our Class A common

stock with no expiration date. Repurchases under these repurchase programs may be made in the open market, in privately

negotiated transactions or otherwise, with the amount and timing of repurchases to be determined at our discretion,

depending on market conditions and corporate needs, or under a trading plan intended to satisfy the affirmative defense

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

conditions of Rule 10b5-1(c)(1) under the Exchange Act. These repurchase programs do not obligate us to acquire any

particular amount of Class A common stock and may be modified, suspended or terminated at any time at the discretion of

our Board. Repurchased shares are subsequently retired and returned to the status of authorized but unissued. As of

June 30, 2025, we had $143.0 million available for future repurchases of our Class A common stock under the new stock

repurchase program.

In March 2024, we repurchased 14.6 million and 6.2 million shares of our Class A common stock (after giving effect to

the automatic conversion of our Class B common stock to Class A common stock upon such repurchase) from related

parties, Francisco Partners IV, L.P. and Francisco Partners IV-A (collectively, "Francisco Partners") and Spectrum Equity VII,

L.P., Spectrum VII Investment Managers' Fund, L.P., and Spectrum VII Co-Investment Fund, L.P. (collectively, "Spectrum"),

respectively, for an aggregate repurchase of 20.9 million shares of our Class A common stock at a price of $7.19 per share,

in each case representing a discount from our closing share price of $7.57 on the date of the transaction execution. The

aggregate consideration for these repurchases was $151.4 million, inclusive of direct costs and estimated excise taxes

associated with these transactions.

In March 2025, we repurchased 10.0 million, 7.0 million, and 3.0 million shares of our Class A common stock (after

giving effect to the automatic conversion of our Class B common stock to Class A common stock upon such repurchase)

from related parties, Francisco Partners, Idea Men, LLC and Spectrum, respectively, for an aggregate repurchase of

20.0 million shares of our Class A common stock at a price of $4.20 per share, in each case representing a discount from

our closing share price of $4.42 as of the last trading day prior to the execution date of these transactions. The aggregate

consideration for these repurchases was $84.9 million, inclusive of direct costs and estimated excise taxes associated with

these transactions.

These related party repurchases were approved by our Board and its Audit and Risk Committee as part of the

aforementioned repurchase programs.

The following table presents information about our repurchases of our Class A common stock:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br>**June 30,** | **Three Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(in thousands)* | **2025** | **2024** | **2025** | **2024** |
| Number of shares repurchased | 10224 |  | 33564 | 21329 |
| Cost of shares repurchased <sup>(1)</sup> | $46352 | $(290) | $147272 | $154524 |

---

_____________________________________________________

(1)Cost of shares repurchased for the three months ended June 30, 2024 represents a change to the estimated

excise taxes associated with past repurchases of our Class A common stock.

**11. Basic and Diluted Earnings Per Share**

The computation of earnings per share for the three and six months ended June 30, 2025 and 2024 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br>**June 30,** | **Three Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(in thousands, except per share amounts)* | **2025** | **2024** | **2025** | **2024** |
| **Numerator:** |  |  |  |  |
| Net income | $12843 | $6694 | $23895 | $5685 |
| **Denominator:** |  |  |  |  |
| Weighted average shares - basic | 356623 | 376254 | 367847 | 386153 |
| Dilutive impact of stock options and restricted <br>stock units<br>| 536 | 8478 | 498 | 7467 |
| Weighted average shares - diluted | 357159 | 384732 | 368345 | 393620 |
| **Earnings per share:** |  |  |  |  |

---

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| Basic | $0.04 | $0.02 | $0.06 | $0.01 |
| Diluted | $0.04 | $0.02 | $0.06 | $0.01 |

---

The following weighted average potentially dilutive shares are excluded from the computation of diluted earnings per

share for the periods presented because including them would have been antidilutive:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br>**June 30,** | **Three Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(in thousands)* | **2025** | **2024** | **2025** | **2024** |
| Stock options and restricted stock units | 57042 | 16164 | 49102 | 18974 |

---

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*You should read the following discussion and analysis of our financial condition and results of operations together with*

*our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report*

*on Form 10-Q, as well as Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of*

*Operations" and Part II, Item 8, "Financial Statements and Supplementary Data" included in our Annual Report on Form 10-*

*K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") on February 27,*

*2025 ("2024 10-K"). This discussion contains forward-looking statements based upon current plans, expectations and beliefs*

*involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking*

*statements as a result of various factors, including those set forth in the "Risk Factors" sections of our 2024 10-K and this*

*Quarterly Report on Form 10-Q and other factors set forth in other parts of this Quarterly Report on Form 10-Q and our*

*filings with the SEC.*

**Glossary of Selected Terminology**

As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires, references to:

• "***we***," "***us***," "***our***," the "***Company***," "***GoodRx***," and similar references refer to GoodRx Holdings, Inc. and its

consolidated subsidiaries.

• "***Co-Founders***" refers to Trevor Bezdek, our Co-Chairman and a director of the Company, and Douglas Hirsch,

a director of the Company.

• "***consumers****"* refer to the general population in the United States that uses or otherwise purchases healthcare

products and services. References to "***our consumers***" or "***GoodRx consumers***" refer to consumers that

have used one or more of our offerings.

• "***discounted price***" refers to a price for a prescription provided on our platform that represents a negotiated

rate provided by one of our PBM partners at a retail pharmacy or under a direct contract with one of our

partner pharmacies. Through our platform, our discounted prices are free to access for consumers by saving a

GoodRx code to their mobile device for their selected prescription and presenting it at the chosen pharmacy.

The term "discounted price" excludes prices we may otherwise source, such as prices from patient assistance

programs for low-income individuals and Medicare prices, and any negotiated rates offered through our

subscription offerings.

• "***GoodRx code****"* refers to codes that can be accessed by our consumers through our apps or websites or that

can be provided to our consumers directly by healthcare professionals, including physicians and pharmacists,

that allow our consumers free access to our discounted prices or a lower list price for their prescriptions when

such code is presented at their chosen pharmacy.

• "***Monthly Active Consumers****"* refers to the number of unique consumers who have used a GoodRx code to

purchase a prescription medication in a given calendar month and have saved money compared to the list

price of the medication. A unique consumer who uses a GoodRx code more than once in a calendar month to

purchase prescription medications is only counted as one Monthly Active Consumer in that month. A unique

consumer who uses a GoodRx code in two or three calendar months within a quarter will be counted as a

Monthly Active Consumer in each such month. Monthly Active Consumers do not include subscribers to our

subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who used our

telehealth offering. When presented for a period longer than a month, Monthly Active Consumers is averaged

over the number of calendar months in such period. For example, a unique consumer who uses a GoodRx

code twice in January, but who did not use our prescription transactions offering again in February or March, is

counted as 1 in January and as 0 in both February and March, thus contributing 0.33 to our Monthly Active

Consumers for such quarter (average of 1, 0 and 0). A unique consumer who uses a GoodRx code in January

and in March, but did not use our prescription transactions offering in February, would be counted as 1 in

January, 0 in February and 1 in March, thus contributing 0.66 to our Monthly Active Consumers for such

quarter. Effective January 1, 2025, Monthly Active Consumers from acquired companies are included

beginning from the acquisition date. Prior to January 1, 2025, Monthly Active Consumers from acquired

companies were only included beginning in the first full quarter following the acquisition.

• "***partner pharmacies***" refers to select licensed pharmacies with whom we have direct contractual agreements.

• "***PBM****"* refers to a pharmacy benefit manager. PBMs aggregate demand to negotiate prescription medication

prices with pharmacies and pharma manufacturers. PBMs find most of their demand through relationships with

insurance companies and employers. However, nearly all PBMs also have consumer direct or cash network

pricing that they negotiate with pharmacies for consumers who choose to purchase prescriptions outside of

insurance.

• "***pharma***" is an abbreviation for pharmaceutical.

• "***savings,****"* "***saved****"* and similar references refer to the difference between the list price for a particular

prescription at a particular pharmacy and the price paid by the GoodRx consumer for that prescription utilizing

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

a GoodRx code available through our platform at that same pharmacy. In certain circumstances, we may show

a list price on our platform when such list price is lower than the negotiated price available using a GoodRx

code and, in certain circumstances, a consumer may use a GoodRx code and pay the list price at a pharmacy

if such list price is lower than the negotiated price available using a GoodRx code. We do not earn revenue

from such transactions, but our savings calculation includes an estimate of the savings achieved by the

consumer because our platform has directed the consumer to the pharmacy with the low list price. This

estimate of savings when the consumer pays the list price is based on internal data and is calculated as the

difference between the average list price across all pharmacies where GoodRx consumers paid the list price

and the average list price paid by consumers in the pharmacies to which we directed them. We do not

calculate savings based on insurance prices as we do not have information about a consumer's specific

coverage or price. We do not believe savings are representative or indicative of our revenue or results of

operations.

• "***subscribers***" and similar references refers to our consumers that are subscribed to our subscription offerings,

2024, and condition-specific related subscriptions which launched in June 2025. References to subscription

plans as of a particular date represents an active subscription to either one of our aforementioned subscription

offerings as of the specified date. For Gold and Kroger Savings, each subscription plan may represent more

than one subscriber since family subscription plans may include multiple members.

Certain monetary amounts, percentages, and other figures included in this Quarterly Report on Form 10-Q have been

subject to rounding adjustments. Percentage amounts included in this Quarterly Report on Form 10-Q have not in all cases

been calculated on the basis of such rounded figures, but on the basis of such amounts prior to rounding. For this reason,

percentage amounts in this Quarterly Report on Form 10-Q may vary from those obtained by performing the same

calculations using the figures in our condensed consolidated financial statements included elsewhere in this Quarterly

Report on Form 10-Q. Certain other amounts that appear in this Quarterly Report on Form 10-Q may not sum due to

rounding.

**Overview**

Our mission is to help Americans save time and money when filling their medications.To achieve this, we are building

the leading consumer-focused digital healthcare platform in the United States. For example, in the second quarter of 2025,

we announced the launch of our first condition-specific subscription program for erectile dysfunction, which offers consumers

a single solution for comprehensive care by bundling the clinician visit, prescription (if deemed medically appropriate by the

treating healthcare provider), and related delivery for a single total subscription price, which we plan to expand into

additional conditions before the end of 2025.

With respect to the healthcare landscape, change has become a constant with positive and negative impacts on our

business. For example, in July 2025, Congress passed a budget bill that cuts federal funding for Medicaid among other

health insurance programs, as well as tightens eligibility requirements and increases the frequency of Medicaid coverage

determinations. Further, copays on prescription medication have continued to trend upward in recent years and we believe

as insurance providers and government programs continue to shift the cost burden more and more to consumers,

consumers are now more than ever searching for sustainable and affordable healthcare solutions which we believe

strengthens our value proposition.

Conversely, we have seen rapid changes in the U.S. retail pharmacy landscape recently with announcements of store

closures and reduction of footprint from various retail pharmacies, including Rite Aid and Walgreens. In early May 2025, Rite

Aid announced its plan to pursue a sale of substantially all of its assets through a voluntary bankruptcy process.

Consequently, we have seen several PBMs remove Rite Aid from their networks, causing immediate cessation in the

associated claims volume, as well as rapid store closures, which altogether have adversely impacted our ability to recapture

these claims in the near term. As an extension of the changing retail pharmacy landscape, we have seen and continue to

expect heightened renegotiations between pharmacies and PBMs, including changes in retailer reimbursement models, as a

result of the pharmacies' increased focus on rationalizing their spending. Furthermore, we saw a material volume reduction

in one of our integrated savings programs, which integrate our competitive discounts and pricing in a seamless experience

at the pharmacy counter for eligible plan members served by certain PBM partners. Integrated savings programs are

operated through PBMs who decide how to implement and manage these programs. Combined, these external factors have

adversely impacted our prescription transactions revenue, financial results, and Monthly Active Consumers that we expect

will continue in the near term with the expected impact to prescription transactions revenue estimated at $35.0 to $40.0

million in 2025.

Despite these near term challenges, we continue to believe that we are well positioned to grow our business over the

long term.

For the three months ended June 30, 2025 as compared to the same period of 2024:

• Revenue increased1% to $203.1 million from $200.6 million;

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

• Net income and net income margin were $12.8 million and 6.3%, respectively, compared to $6.7 million and

3.3%, respectively; and

• Adjusted EBITDA and Adjusted EBITDA Margin were $69.4 million and 34.2%, respectively, compared to $65.4

million and 32.6%, respectively.

For the six months ended June 30, 2025 as compared to the same period of 2024:

• Revenue increased2% to $406.0 million from $398.5 million;

• Net income and net income margin were $23.9 million and 5.9%, respectively, compared to $5.7 million and

1.4%, respectively; and

• Adjusted EBITDA and Adjusted EBITDA Margin were $139.2 million and 34.3%, respectively, compared to

$128.2 million and 32.2%, respectively.

Revenue, net income and net income margin are financial measures prepared in conformity with accounting principles

generally accepted in the United States ("GAAP"). Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial

measures. For a reconciliation and presentation of Adjusted EBITDA and Adjusted EBITDA Margin to the most directly

comparable GAAP financial measures, information about why we consider Adjusted EBITDA and Adjusted EBITDA Margin

useful and a discussion of the material risks and limitations of these measures, please see "Key Financial and Operating

Metrics—Non-GAAP Financial Measures" below.

**Key Financial and Operating Metrics**

We use Monthly Active Consumers, subscription plans, Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA

Margin to assess our performance, make strategic and offering decisions and build our financial projections. The number of

Monthly Active Consumers and subscription plans are key indicators of the scale of our consumer base and a gauge for our

marketing and engagement efforts. We believe these operating metrics reflect our scale, growth and engagement with

consumers.

We exited the second quarter of 2025 with over6 million prescription-related consumers that used GoodRx across our

prescription transactions and subscription offerings. Our prescription-related consumers represent the sum of Monthly Active

Consumers for the three months ended June 30, 2025 and subscribers to our subscription plans as of June 30, 2025.

***Monthly Active Consumers***

The factors described in the "Overview" section have adversely impacted our Monthly Active Consumers in the second

quarter of 2025 and are expected to contribute to the year-over-year decline in Monthly Active Consumers in the near term.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| *(in millions)* | **June 30,**<br>**2025**<br>| **March 31,**<br>**2025**<br>| **December 31,**<br>**2024**<br>| **September 30,**<br>**2024**<br>| **June 30,**<br>**2024**<br>| **March 31,**<br>**2024**<br>|
| Monthly Active Consumers | 5.7 | 6.4 | 6.6 | 6.5 | 6.6 | 6.7 |

---

***Subscription Plans***

Subscription plans through the second quarter of 2024 included subscription plans for Kroger Savings, which sunset in

July 2024.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **As of** | **As of** | **As of** | **As of** | **As of** | **As of** |
| *(in thousands)* | **June 30,**<br>**2025**<br>| **March 31,**<br>**2025**<br>| **December 31,**<br>**2024**<br>| **September 30,**<br>**2024**<br>| **June 30,**<br>**2024**<br>| **March 31,**<br>**2024**<br>|
| Subscription plans | 668 | 680 | 684 | 701 | 696 | 778 |

---

***Non-GAAP Financial Measures***

Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA Margin are key measures we use to assess our financial

performance and are also used for internal planning and forecasting purposes. We believe Adjusted Revenue, Adjusted

EBITDA and Adjusted EBITDA Margin are helpful to investors, analysts and other interested parties because they can assist

in providing a more consistent and comparable overview of our operations across our historical financial periods. In addition,

these measures are frequently used by analysts, investors and other interested parties to evaluate and assess performance.

We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated

with restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

or future underlying performance of the business. For the three and six months ended June 30, 2025 and 2024, revenue

was equal to Adjusted Revenue.

We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and

amortization, and as further adjusted, as applicable, for acquisition related expenses, stock-based compensation expense,

payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss

on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of business and other

income or expense, net. These excluded items are either non-cash charges or such that we believe do not represent our

underlying core operating performance and that their exclusion provides investors with a better understanding of the factors

and trends affecting our business. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of Adjusted

Revenue.

Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are

presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to

financial information presented in accordance with GAAP. These measures have certain limitations in that they do not

include the impact of certain costs that are reflected in our condensed consolidated statements of operations that are

necessary to run our business. Other companies, including other companies in our industry, may not use these measures or

may calculate these measures differently than as presented in this Quarterly Report on Form 10-Q, limiting their usefulness

as comparative measures.

The following table presents a reconciliation of net income, the most directly comparable financial measure calculated in

accordance with GAAP, to Adjusted EBITDA, and presents net income margin, the most directly comparable financial

measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br>**June 30,** | **Three Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(dollars in thousands)* | **2025** | **2024** | **2025** | **2024** |
| Net income | $12843 | $6694 | $23895 | $5685 |
| Adjusted to exclude the following: |  |  |  |  |
| Interest income | (2803) | (6334) | (6735) | (13889) |
| Interest expense | 10729 | 14566 | 21373 | 29209 |
| Income tax expense | 6734 | 4952 | 12350 | 6254 |
| Depreciation and amortization | 19729 | 16965 | 40641 | 32907 |
| Other income | (694) |  | (694) |  |
| Financing related expenses <sup>(1)</sup> |  | 392 |  | 832 |
| Acquisition related expenses <sup>(2)</sup> |  | 174 | 26 | 348 |
| Restructuring related expenses <sup>(3)</sup> | 546 | 566 | 1765 | 441 |
| Legal settlement expenses <sup>(4)</sup> | 355 |  | 355 | 13000 |
| Stock-based compensation expense | 21415 | 26590 | 40589 | 51686 |
| Payroll tax expense related to stock-based <br>compensation<br>| 549 | 847 | 1234 | 1726 |
| Loss on operating lease asset <sup>(5)</sup> |  |  | 4409 |  |
| Adjusted EBITDA | $69403 | $65412 | $139208 | $128199 |
| Revenue | $203070 | $200610 | $406040 | $398490 |
| Net income margin | 6.3% | 3.3% | 5.9% | 1.4% |
| Adjusted EBITDA Margin | 34.2% | 32.6% | 34.3% | 32.2% |

---

_____________________________________________________

(1)Financing related expenses include third-party fees related to proposed financings.

(2)Acquisition related expenses principally include costs for actual or planned acquisitions including related third-party

fees, legal, consulting and other expenditures, and as applicable, severance costs and retention bonuses to

employees related to acquisitions and change in fair value of contingent consideration. From time to time,

acquisition related expenses may also include similar transaction related costs for business dispositions.

(3)Restructuring related expenses include costs for various workforce optimization and organizational changes to

better align with our strategic goals and future scale including employee severance and other personnel related

costs, contract termination costs, and from time to time may also include losses from the disposal of certain

technology and certain capitalized software.

(4)Legal settlement expenses consist of periodic settlement costs for significant or unusual litigation matters.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

(5)Loss on operating lease asset represents losses incurred from time to time relating to the impairment or

abandonment of leased office space.

**Components of our Results of Operations**

For a description of the components of our results of operations, refer to Note 2 to our audited consolidated financial

statements included in our 2024 10-K. In addition, for a description of primary drivers that may cause our revenue, costs and

operating expenses to fluctuate from period to period, including seasonality, refer to Part II, Item 7, "Management's

Discussion and Analysis of Financial Condition and Results of Operations" included in our 2024 10-K.

**Results of Operations**

***Three Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2024***

The following table sets forth our results of operations for the three months ended June 30, 2025and2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(dollars in thousands)* | **Three** <br>**Months** <br>**Ended**<br>**June 30,** <br>**2025**<br>| **% of Total** <br>**Revenue**<br>| **Three** <br>**Months** <br>**Ended**<br>**June 30,** <br>**2024**<br>| **% of Total** <br>**Revenue**<br>| **Change ($)** | **Change (%)** |
| Revenue: |  |  |  |  |  |  |
| Prescription transactions revenue | $143064 | 70% | $146748 | 73% | $(3684) | (3%) |
| Subscription revenue | 20463 | 10% | 21953 | 11% | (1490) | (7%) |
| Pharma manufacturer solutions <br>revenue<br>| 34981 | 17% | 26504 | 13% | 8477 | 32% |
| Other revenue | 4562 | 2% | 5405 | 3% | (843) | (16%) |
| Total revenue | 203070 |  | 200610 |  |  |  |
| Costs and operating expenses: |  |  |  |  |  |  |
| Cost of revenue, exclusive of <br>depreciation and amortization <br>presented separately below<br>| 13350 | 7% | 11870 | 6% | 1480 | 12% |
| Product development and technology | 29933 | 15% | 30854 | 15% | (921) | (3%) |
| Sales and marketing | 84870 | 42% | 93454 | 47% | (8584) | (9%) |
| General and administrative | 28379 | 14% | 27589 | 14% | 790 | 3% |
| Depreciation and amortization | 19729 | 10% | 16965 | 8% | 2764 | 16% |
| Total costs and operating expenses | 176261 |  | 180732 |  |  |  |
| Operating income | 26809 |  | 19878 |  |  |  |
| Other expense, net: |  |  |  |  |  |  |
| Other income | 694 | 0% |  | 0% | 694 | n/m |
| Interest income | 2803 | 1% | 6334 | 3% | (3531) | (56%) |
| Interest expense | (10729) | 5% | (14566) | 7% | 3837 | (26%) |
| Total other expense, net | (7232) |  | (8232) |  |  |  |
| Income before income taxes | 19577 |  | 11646 |  |  |  |
| Income tax expense | (6734) | 3% | (4952) | 2% | (1782) | 36% |
| Net income | $12843 |  | $6694 |  |  |  |

---

***Revenue***

All of our revenue has been generated in the United States.

Prescription transactions revenue decreased$3.7 million, or 3%, year-over-year, primarily driven by a 14%decrease in

the number of our Monthly Active Consumers, due to the broader changes in the retail pharmacy landscape including store

closures and volume reduction in one of our integrated savings programs as discussed above, partially offset by improved

unit economics related to contracting with certain of our customers and partners and favorable changes in sales mix.Our

acquisition of VCRx (see Note 3 to our condensed consolidated financial statements included elsewhere in this Quarterly

Report on Form 10-Q) did not materially contribute to the year-over-year changes in prescription transactions revenue and

Monthly Active Consumers.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

Subscription revenue decreased$1.5 million, or 7%, year-over-year, primarily driven by a decrease in the number of

subscription plans with 668 thousand subscription plans as of June 30, 2025 compared to 696 thousand as ofJune 30,

2024. Pharma manufacturer solutions revenue increased$8.5 million, or 32%, year-over-year, driven by organic growth as we

continued to expand our market penetration with pharma manufacturers and other customers. We expect pharma

manufacturer solutions to grow as a percentage of total revenue in the near to medium term as we continue to scale and

expand available services, capabilities and platforms of our pharma manufacturer solutions offering.

***Costs and Operating Expenses***

*Cost of revenue, exclusive of depreciation and amortization*

Cost of revenue increased$1.5 million, or 12%, year-over-year, primarily driven by a $1.7 million increase in processing

fees.

*Product development and technology*

Product development and technology expenses remained relatively flat year-over-year, primarily driven by a decrease in

payroll and related costs largely due to lower average headcount and higher capitalization of such costs related to the

development of internal-use software, partially offset by an increase in third-party services and contractors associated with

non-capitalizable product development activities.

*Sales and marketing*

Sales and marketing expenses decreased$8.6 million, or 9%, year-over-year, primarily driven by a $4.3 million

decrease in advertising expenses, a $2.6 million decrease in third-party marketing expenses, and a $2.1 million decrease in

payroll and related expenses largely due to lower stock-based compensation expense as a result of changes in our

employee composition.

*General and administrative*

General and administrative expenses remained relatively flat year-over-year, primarily driven by a decrease in stock-

based compensation expense related to awards granted to our Co-Founders in 2020 that fully vested by the end of 2024,

partially offset by an increase in professional fees.

*Depreciation and amortization*

Depreciation and amortization expenses increased$2.8 million, or 16%, year-over-year, primarily driven by higher

amortization related to capitalized software due to higher capitalization costs for platform improvements and the introduction

of new products and features.

***Interest Income***

Interest income decreased by $3.5 million, or 56%, year-over-year, primarily due to lower average balance of cash

equivalents held in U.S. treasury securities money market funds and lower interest rates.

***Interest Expense***

Interest expense decreased by $3.8 million, or 26%, year-over-year, primarily due to lower average debt balances and

lower interest rates.

***Income Taxes***

For the three months ended June 30, 2025 and 2024, we had income tax expense of $6.7 million and $5.0 million,

respectively, and an effective income tax rate of 34.4% and 42.5%, respectively. The year-over-year increase in income tax

expense was primarily driven by an increase in income before income taxes and the tax effects from our equity awards,

partially offset by a decrease in the estimated annual effective income tax rate.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

***Six Months Ended June 30, 2025 Compared to Six Months Ended June 30, 2024***

The following table sets forth our results of operations for the six months ended June 30, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(dollars in thousands)* | **Six Months** <br>**Ended**<br>**June 30,** <br>**2025**<br>| **% of Total** <br>**Revenue**<br>| **Six Months** <br>**Ended**<br>**June 30,** <br>**2024**<br>| **% of Total** <br>**Revenue**<br>| **Change ($)** | **Change (%)** |
| Revenue: |  |  |  |  |  |  |
| Prescription transactions revenue | $291987 | 72% | $292143 | 73% | $(156) | 0% |
| Subscription revenue | 41480 | 10% | 44554 | 11% | (3074) | (7%) |
| Pharma manufacturer solutions <br>revenue<br>| 63629 | 16% | 51013 | 13% | 12616 | 25% |
| Other revenue | 8944 | 2% | 10780 | 3% | (1836) | (17%) |
| Total revenue | 406040 |  | 398490 |  |  |  |
| Costs and operating expenses: |  |  |  |  |  |  |
| Cost of revenue, exclusive of <br>depreciation and amortization <br>presented separately below<br>| 26714 | 7% | 24338 | 6% | 2376 | 10% |
| Product development and technology | 61075 | 15% | 61871 | 16% | (796) | (1%) |
| Sales and marketing | 169412 | 42% | 183418 | 46% | (14006) | (8%) |
| General and administrative | 58009 | 14% | 68697 | 17% | (10688) | (16%) |
| Depreciation and amortization | 40641 | 10% | 32907 | 8% | 7734 | 24% |
| Total costs and operating expenses | 355851 |  | 371231 |  |  |  |
| Operating income | 50189 |  | 27259 |  |  |  |
| Other expense, net: |  |  |  |  |  |  |
| Other income | 694 | 0% |  | 0% | 694 | n/m |
| Interest income | 6735 | 2% | 13889 | 3% | (7154) | (52%) |
| Interest expense | (21373) | 5% | (29209) | 7% | 7836 | (27%) |
| Total other expense, net | (13944) |  | (15320) |  |  |  |
| Income before income taxes | 36245 |  | 11939 |  |  |  |
| Income tax expense | (12350) | 3% | (6254) | 2% | (6096) | 97% |
| Net income | $23895 |  | $5685 |  |  |  |

---

***Revenue***

Prescription transactions revenue remained relatively flat year-over-year, primarily driven by a 9%decrease in the

number of our Monthly Active Consumers, due to the broader changes in the retail pharmacy landscape including store

closures and volume reduction in one of our integrated savings programs as discussed above, substantially offset by

improved unit economics related to contracting with certain of our customers and partners and favorable changes in sales

mix. Our acquisition of VCRx (see Note 3 to our condensed consolidated financial statements included elsewhere in this

Quarterly Report on Form 10-Q) did not materially contribute to the year-over-year changes in prescription transactions

revenue and Monthly Active Consumers.

The year-over-year changes in subscription revenue and pharma manufacturer solutions revenue were driven by the

same factors described above for the three months ended June 30, 2025 compared to the same period of 2024.

For expected revenue trends, see our discussion and analysis above for the three months ended June 30, 2025

compared to the same period of 2024.

***Costs and Operating Expenses***

*Cost of revenue, exclusive of depreciation and amortization*

Cost of revenue increased$2.4 million, or 10%, year-over-year, primarilydriven by an increase in processing fees.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

*Product development and technology*

Product development and technology expenses remained relatively flat year-over-year, primarily driven by the same

factors described above for the three months ended June 30, 2025 compared to the same period of 2024.

*Sales and marketing*

Sales and marketing expenses decreased$14.0 million, or 8%, year-over-year, primarily driven by a $5.3 million

decrease in advertising expenses, a $5.2 million decrease in third-party marketing expenses, and a $4.0 million decrease in

payroll and related expenses largely due to lower stock-based compensation expense as a result of changes in our

employee composition.

*General and administrative*

General and administrative expenses decreased$10.7 million, or 16%, year-over-year, primarily driven by a net $13.0

million estimated legal settlement loss recognized in the first quarter of 2024 with respect to an ongoing class action litigation

and a $3.8 million decrease in stock-based compensation expense related to awards granted to our Co-Founders in 2020

that fully vested by the end of 2024. The impact of these drivers was partially offset by a $4.4 million impairment loss related

to a leased office space we recognized in the first quarter of 2025 and a $1.5 million increase in professional fees.

*Depreciation and amortization*

Depreciation and amortization expenses increased$7.7 million, or 24%, year-over-year, primarily driven by the same

factors described above for the three months ended June 30, 2025 compared to the same period of 2024.

***Interest Income, Interest Expense and Income Taxes***

The year-over-year changes in interest income, interest expense and income taxes were primarily driven by the same

factors described above for the three months ended June 30, 2025 compared to the same period of 2024.

**Liquidity and Capital Resources**

Since our inception, we have financed our operations primarily through net cash provided by operating activities, equity

issuances, and borrowings under our long-term debt arrangements. As of June 30, 2025, our principal sources of liquidity

are our cash and cash equivalents and borrowings available under our $100.0 million secured revolving credit facility, of

which $12.0 million matured onJuly 11, 2025 and $88.0 million will mature on April 10, 2029. As of June 30, 2025, we had

cash and cash equivalents of $281.3 million and $92.2 million available under our revolving credit facility.

Other than as disclosed in Note 8 to our condensed consolidated financial statements appearing elsewhere in this

Quarterly Report on Form 10-Q, as of June 30, 2025, there were no material changes to our primary short-term and long-

term requirements for liquidity and capital or to our contractual commitments as disclosed in Part II, Item 7, "Management's

Discussion and Analysis of Financial Condition and Results of Operations" of our 2024 10-K.

Based on our current conditions, we believe that our net cash provided by operating activities and cash on hand will be

adequate to meet our operating, investing and financing needs for at least the next twelve months from the date of the

issuance of the accompanying unaudited condensed consolidated financial statements. Our future capital requirements will

depend on many factors, including the growth of our business, the timing and extent of investments, sales and marketing

activities, and many other factors as described in Part I, Item 1A, "Risk Factors" of our 2024 10-K.

If necessary, we may borrow funds under our revolving credit facility to finance our liquidity requirements, subject to

customary borrowing conditions. To the extent additional funds are necessary to meet our long-term liquidity needs as we

continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional

indebtedness, additional equity financings or a combination of these potential sources of funds; however, such financing

may not be available on favorable terms, or at all. In particular, the current economic uncertainty, including rising inflation,

new or increased tariffs and socio-political events, has resulted in, and may continue to result in, significant disruption of

global financial markets, including rising interest rates, which could reduce our ability to access capital. If we are unable to

raise additional funds when needed or on the terms desired, our business, financial condition and results of operations could

be adversely affected.

***Holding Company Status***

GoodRx Holdings, Inc. is a holding company that does not conduct any business operations of its own. As a result,

GoodRx Holdings, Inc. is largely dependent upon cash distributions and other transfers from its subsidiaries to meet its

obligations and to make future dividend payments, if any. Our debt arrangements contain covenants restricting payments of

dividends by our subsidiaries, including GoodRx, Inc., unless certain conditions are met. These covenants provide for

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

certain exceptions for specific types of payments. Based on these restrictions, all of the net assets of GoodRx, Inc. were

restricted pursuant to the terms of our debt arrangements as of June 30, 2025. Since the restricted net assets of GoodRx,

Inc. and its subsidiaries exceed 25% of our consolidated net assets, in accordance with Regulation S-X, see Note 18 to our

consolidated financial statements included in our 2024 10-K for the condensed parent company financial information of

GoodRx Holdings, Inc.

***Cash Flows***

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended**<br>**June 30,** | **Six Months Ended**<br>**June 30,** |
| *(in thousands)* | **2025** | **2024** |
| Net cash provided by operating activities | $58993 | $52287 |
| Net cash used in investing activities | (70191) | (37844) |
| Net cash used in financing activities | (155830) | (161836) |
| Net change in cash and cash equivalents | $(167028) | $(147393) |

---

*Net cash provided by operating activities*

The $6.7 million year-over-year increase in net cash provided by operations was driven by a $19.1 million increase in

net income after adjusting for non-cash adjustments, partially offset by a $12.3 millionincrease in cash outflow from changes

in operating assets and liabilities. Changes in operating assets and liabilities were principally driven by the timing of

payments of prepaid services and accounts payable, income tax payments and refunds, as well as collections of accounts

receivable.

*Net cash used in investing activities*

The $32.3 million year-over-year increase in net cash used in investing activities was primarily driven by a $30.0 million

increase in cash paid for the acquisition of a business.

*Net cash used in financing activities*

The $6.0 million year-over-year decrease in net cash used in financing activities was primarily driven by a $7.3 million

decrease in payments for repurchases of our Class A common stock, a $7.7 milliondecrease in employee taxes paid related

to net share settlement of equity awards, and a $2.8 milliondecrease in payments on our term loans as a result of our

refinancing in July 2024. The impact from these drivers was partially offset by a $11.8 milliondecrease in proceeds from the

exercise of stock options.

**Recent Accounting Pronouncements**

Refer to Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on

Form 10-Q.

**Critical Accounting Policies and Estimates**

During the three months ended June 30, 2025, there have been no significant changes to our critical accounting policies

and estimates compared with those disclosed in Part II, Item 7, "Management's Discussion and Analysis of Financial

Condition and Results of Operations" of our 2024 10-K.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

There have been no material changes in our market risk from the disclosure included in Part II, Item 7A, "Quantitative

and Qualitative Disclosures About Market Risk" of our 2024 10-K.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of

the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and

procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal

executive officer and principal financial officer concluded that, as of June 30, 2025, our disclosure controls and procedures

were effective.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**Changes in Internal Control Over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)

under the Exchange Act) during the three months ended June 30, 2025 that have materially affected, or are reasonably

likely to materially affect, our internal control over financial reporting.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

The information required under this Part II, Item 1 is set forth in Note 8 to our condensed consolidated financial

statements included in this Quarterly Report on Form 10-Q and is incorporated herein by this reference.

**Item 1A. Risk Factors**

For a discussion of potential risks and uncertainties related to us, see the information included in Part I, Item 1A, "Risk

Factors" of our 2024 10-K. There have been no material changes to the risk factors previously disclosed in our 2024 10-K,

except as noted below:

***General economic factors, natural disasters or other unexpected events may adversely affect our business,***

***financial performance and results of operations.***

Although we only operate in the United States, our business, financial performance and results of operations depend in

part on worldwide macroeconomic economic conditions and their impact on consumer spending. Recessionary economic

cycles, changing interest rates, volatile fuel and energy costs, inflation, levels of unemployment, conditions in the residential

real estate and mortgage markets, access to credit, consumer debt levels, tariffs, government spending freezes, unsettled

financial markets and other economic factors that may affect costs of manufacturing prescription medications, consumer

spending or buying habits could materially and adversely affect our customers, our consumers, and demand for our

offerings. Volatility in the financial markets and deterioration in economic conditions, increasing inflation or increasing

unemployment levels has also had and may continue to have a negative impact on consumer spending patterns. Changes

and uncertainty can, among other things, reduce or shift spending away from medical treatments, procedures and doctors'

office visits.

In addition, negative national or global economic conditions have adversely affected the PBMs, partner pharmacies and

pharma manufacturers we contract with and their associated industry participants, financial performance, liquidity and

access to capital, and may continue to impact them. This may affect their ability to renew contracts with us on the same or

better terms, which could impact the competitiveness of the discounted prices we are able to offer our consumers. Trade

barriers, duties, tariffs, and retaliatory measures by the U.S. and other governments may impact the pharma manufacturers

we contract with by increasing their costs of business, which could cause them to decrease their marketing spend on our

offerings. All of these factors may be exacerbated by global financial conditions and other geopolitical factors, which could

harm our business, financial condition and results of operations.

Economic factors such as increased insurance and healthcare costs, commodity prices, tariffs, shipping costs, inflation,

higher costs of labor, and changes in or interpretations of other laws, regulations and taxes may also increase our costs and

make our offerings less competitive, increase general and administrative expenses, and otherwise adversely affect our

financial condition and results of operations.

Additionally, global public health crises, natural disasters, such as earthquakes and wildfires, and other adverse weather

and climate conditions, political crises, such as terrorist attacks, war and other political instability or other unexpected

events, could disrupt our operations, internet or mobile networks or the operations of PBMs and their pharmacy networks.

For example, our corporate headquarters and other facilities are located in California, which in the past has experienced

both severe earthquakes and wildfires. Certain of these events may become more frequent or intense as a result of climate

change or other environmental or social pressures. For more information, see our risk factor titled "We are subject to a

series of risks related to climate change" previously disclosed in our 2024 10-K. If any of these events occurs, our business

could be adversely affected.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Unregistered Sales of Equity Securities**

None.

**Use of Proceeds**

On September 25, 2020, we completed our IPO. All shares sold were registered pursuant to a registration statement on

Form S-1 (File No. 333-248465), as amended (the "Registration Statement"), declared effective by the SEC on September

22, 2020.

There have been no material changes in the expected use of the net proceeds from our IPO as described in our

Registration Statement. As of June 30, 2025, we estimated we had used approximately $730.4 million of the net proceeds

from our IPO: (i) $184.4 million for the acquisition of businesses that complement our business; (ii) $366.0 million for the

repurchases of our Class A common stock; (iii) $160.0 million for the repayment of our outstanding debt obligations; and (iv)

$20.0 million for working capital and other general corporate purposes. As of June 30, 2025, we had $156.5 million

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

estimated remaining net proceeds from our IPO which have been invested in investment grade, interest-bearing

instruments.

**Issuer Repurchases of Equity Securities**

The following table presents information with respect to our repurchases of our Class A common stock during the three

months ended June 30, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of** <br>**Shares Repurchased** <sup>(1)</sup><br>| **Average Price Paid** <br>**per Share** <sup>(2)</sup><br>| **Total Number of Shares**<br>**Repurchased as Part of**<br>**Publicly Announced** <br>**Program** <sup>(1)</sup><br>| **Approximate Dollar**<br>**Value of Shares that**<br>**May Yet Be** <br>**Repurchased**<br>**Under the Program**<br>*(in thousands)*<br>|
| April 1 - 30 | 3989715 | $4.48 | 3989715 | $171502 |
| May 1 - 31 | 1367653 | $4.52 | 1367653 | $165320 |
| June 1 - 30 | 4866921 | $4.58 | 4866921 | $143024 |
| Total | 10224289 |  | 10224289 |  |

---

_____________________________________________________

(1)The repurchases are being executed from time to time, subject to general business and market conditions and

other investment opportunities, through open market purchases or privately negotiated transactions, which may

include repurchases through a trading plan intended to satisfy the affirmative defense conditions of Rule

10b5-1(c)(1) under the Exchange Act. See Note 10 to our condensed consolidated financial statements included

elsewhere in this Quarterly Report on Form 10-Q for additional information related to our current $450.0 million

stock repurchase program with no expiration date, which was publicly announced on February 29, 2024.

(2)Average price paid per share includes direct costs and estimated excise taxes associated with the repurchases.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

**Insider Trading Arrangements**

During the three months ended June 30, 2025, none of our directors or officers (as defined in Section 16 of the

Exchange Act), adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our

securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any "non-

Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K of the Exchange Act).

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**Item 6. Exhibits**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed/**<br>**Furnished**<br>**Herewith** |
| <br>**Exhibit**<br>**Number**<br>| <br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing**<br>**Date**<br>| **Filed/**<br>**Furnished**<br>**Herewith** |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1809519/000119312520256438/d35545dex31.htm)</u> | 8-K | 001-39549 | 3.1 | 9/28/20 |  |
| 3.2 | <u>[Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/0001809519/000119312520256438/d35545dex32.htm)</u> | 8-K | 001-39549 | 3.2 | 9/28/20 |  |
| 4.1 | <u>[Form of Certificate of Class A Common Stock](https://www.sec.gov/Archives/edgar/data/1809519/000119312520234662/d949310dex41.htm)</u> | S-1 | 333-248465 | 4.1 | 8/28/20 |  |
| 4.2 | <u>[Form of Certificate of Class B Common Stock](https://www.sec.gov/Archives/edgar/data/1809519/000119312520254694/d62083dex44.htm)</u> | S-8 | 333-249069 | 4.4 | 9/25/20 |  |
| 31.1 | <u>[Certification of Chief Executive Officer pursuant to Rule](gdrxq225-ex311.htm)</u><br><u>[13a-14(a)/15d-14(a)](gdrxq225-ex311.htm)</u><br>|  |  |  |  | \* |
| 31.2 | <u>[Certification of Chief Financial Officer pursuant to Rule](gdrxq225-ex312.htm)</u><br><u>[13a-14(a)/15d-14(a)](gdrxq225-ex312.htm)</u><br>|  |  |  |  | \* |
| 32.1 | <u>[Certification of Chief Executive Officer pursuant to 18](gdrxq225-ex321.htm)</u><br><u>[U.S.C. Section 1350](gdrxq225-ex321.htm)</u><br>|  |  |  |  | \*\* |
| 32.2 | <u>[Certification of Chief Financial Officer pursuant to 18 U.S.C.](gdrxq225-ex322.htm)</u><br><u>[Section 1350](gdrxq225-ex322.htm)</u><br>|  |  |  |  | \*\* |
| 101.INS | Inline XBRL Instance Document – the instance document <br>does not appear in the Interactive Data File because its <br>XBRL tags are embedded within the Inline XBRL document<br>|  |  |  |  | \* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  | \* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase <br>Document<br>|  |  |  |  | \* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase <br>Document<br>|  |  |  |  | \* |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase <br>Document<br>|  |  |  |  | \* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase <br>Document<br>|  |  |  |  | \* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL <br>and contained in Exhibit 101)<br>|  |  |  |  | \* |

---

_____________________________________________________

\*Filed herewith.

\*\*Furnished herewith.

<u>[**Table of Contents**](#ia7bcc97e7330412a99b7141e522e061e_10)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | GOODRX HOLDINGS, INC. | GOODRX HOLDINGS, INC. |
| Date: August 6, 2025 | By: | /s/ Wendy Barnes |
|  |  | Wendy Barnes |
|  |  | Chief Executive Officer & President |
|  |  | *(Principal Executive Officer)*  |
| Date: August 6, 2025 | By: | /s/ Christopher McGinnis |
|  |  | Christopher McGinnis |
|  |  | Chief Financial Officer & Treasurer |
|  |  | *(Principal Financial Officer)* |
| Date: August 6, 2025 | By: | /s/ Romin Nabiey |
|  |  | Romin Nabiey |
|  |  | Chief Accounting Officer |
|  |  | *(Principal Accounting Officer)* |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION** 

I, Wendy Barnes, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of GoodRx Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a

material fact necessary to make the statements made, in light of the circumstances under which such statements

were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly

present in all material respects the financial condition, results of operations and cash flows of the registrant as of,

and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls

and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial

reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to

be designed under our supervision, to ensure that material information relating to the registrant, including

its consolidated subsidiaries, is made known to us by others within those entities, particularly during the

period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial

reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability

of financial reporting and the preparation of financial statements for external purposes in accordance with

generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this

report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of

the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred

during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an

annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's

internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control

over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or

persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over

financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,

summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant

role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 6, 2025 | By: | /s/ Wendy Barnes |
|  |  | Wendy Barnes |
|  |  | Chief Executive Officer & President<br>*(Principal Executive Officer)*<br>|

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION** 

I, Christopher McGinnis, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of GoodRx Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a

material fact necessary to make the statements made, in light of the circumstances under which such statements

were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly

present in all material respects the financial condition, results of operations and cash flows of the registrant as of,

and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls

and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial

reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to

be designed under our supervision, to ensure that material information relating to the registrant, including

its consolidated subsidiaries, is made known to us by others within those entities, particularly during the

period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial

reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability

of financial reporting and the preparation of financial statements for external purposes in accordance with

generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this

report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of

the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred

during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an

annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's

internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control

over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or

persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over

financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,

summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant

role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 6, 2025 | By: | /s/ Christopher McGinnis |
|  |  | Christopher McGinnis |
|  |  | Chief Financial Officer & Treasurer<br>*(Principal Financial Officer)*<br>|

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of GoodRx Holdings, Inc. (the "Company") for the period ended

June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to

18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;

and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of

operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: August 6, 2025 | By: | /s/ Wendy Barnes |
|  |  | Wendy Barnes |
|  |  | Chief Executive Officer & President<br>*(Principal Executive Officer)*<br>|

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of GoodRx Holdings, Inc. (the "Company") for the period ended

June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to

18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;

and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of

operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: August 6, 2025 | By: | /s/ Christopher McGinnis |
|  |  | Christopher McGinnis |
|  |  | Chief Financial Officer & Treasurer<br>*(Principal Financial Officer)*<br>|

---